Windlas Biotech has 4 manufacturing services positioned at Dehradun in Uttarakhand.
Windlas Biotech has filed preliminary papers with markets regulator Sebi for an preliminary public supply. The major market providing will embrace a contemporary challenge of Rs 165 crore and a proposal on the market of as much as 5,142,067 shares, as per the draft doc filed with the market regulator. The firm can also be in session with its ebook working managers to boost Rs 50 crore by a pre-IPO placement.
The firm will utilise the IPO proceeds for increasing its Dehradun Plant–IV and including injectables dosage functionality on the facility at Dehradun Plant-II. It will even be used the funds for incremental working capital necessities, reimbursement/ prepayment of borrowings and common company functions.
Windlas Biotech is into home pharmaceutical formulations contract improvement and manufacturing enterprise, and has 4 manufacturing services positioned at Dehradun in Uttarakhand.
SBI Capital Markets, DAM Capital and IIFL Securities are the ebook working lead managers to the general public challenge.
